Company intelligence / Profile preview

Verlyx Pharma Inc.

Montreal, Quebec, Canadaverlyx.com ↗

Ownership: Private
Development stage: Other

Overview

Verlyx Pharma Inc. was a Montreal-based clinical-stage biopharmaceutical company focused on developing liver-targeting therapeutic agents, including its lead compound VLX103 and analogs for gastrointestinal diseases. The company also developed new formulations of pentamidine targeting liver cancers such as hepatocellular carcinoma. At least one Phase I clinical trial was completed with an oral pentamidine formulation. In February 2024, the company was acquired by Odan Laboratories Ltd., after which it ceased independent operations. No products had received regulatory approval at the time of acquisition.

Therapeutic areas: GastroenterologyOncology
Modalities: Small molecules
Industry: Biotech

Beyond the preview

Go deeper on Verlyx Pharma Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verlyx Pharma Inc..